- GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6BGSK is making one of the largest biotech acquisitions in its history to gain access to two experimental lung cancer medicines that are due for FDA approval decisions later this year. The UK drugm…Endpoints · 1mo ago↗ source
- #ADA26: AstraZeneca's GLP-1 pill cuts weight by 10.5% after six monthsThe race to be third to market with an obesity pill has a number of contenders, including Roche, Pfizer and Structure Therapeutics. On Monday, AstraZeneca set out its own stall with data on a pill ...Endpoints · 1mo ago↗ source
- Incyte CEO sees $2B Vega deal aiding a post-Jakafi futureBill Meury has been in or led the C-suite of several biopharma companies that have constructed multibillion-dollar exits over the past decade: Allergan, Karuna and Anthos. Now, he’s the one buyin…